Showing 1 - 4 results of 4 for search 'Maria Grazia Pau', query time: 0.01s Refine Results
  1. 1
    Safety, reactogenicity, and immunogenicity of Ad26.COV2.S co-administered with a quadrivalent standard-dose or high-dose seasonal influenza vaccine: a non-inferiority randomised controlled trialResearch in context

    Safety, reactogenicity, and immunogenicity of Ad26.COV2.S co-administered with a quadrivalent standard-dose or high-dose seasonal influenza vaccine: a non-inferiority randomised co... by Gabriela Tapia-Calle, Gloria Aguilar, Nathalie Vaissiere, Carla Truyers, Pedro Ylisastigui, Erik Buntinx, Mathieu Le Gars, Frank Struyf, Gert Scheper, Macaya Douoguih, Javier Ruiz-Guiñazú, Robert Patrizi, Wai Ling, Sanne de Ridder, Marit de Groot, Maria Grazia Pau, Gerald Weidinger, Srividya Pradeep, Nadine Salisch, Sophie Cambre

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults.

    A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated... by Sharon Sheehan, Stephanie A Harris, Iman Satti, David A Hokey, Veerabadran Dheenadhayalan, Lisa Stockdale, Zita-Rose Manjaly Thomas, Alice Minhinnick, Morven Wilkie, Samantha Vermaak, Joel Meyer, Matthew K O'Shea, Maria Grazia Pau, Isabella Versteege, Macaya Douoguih, Jenny Hendriks, Jerald Sadoff, Bernard Landry, Paul Moss, Helen McShane

    Published 2015-01-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age.

    A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite... by Alphonse Ouédraogo, Alfred B Tiono, Désiré Kargougou, Jean Baptiste Yaro, Esperance Ouédraogo, Youssouf Kaboré, David Kangoye, Edith C Bougouma, Adama Gansane, Noelie Henri, Amidou Diarra, Souleymane Sanon, Issiaka Soulama, Amadou T Konate, Nora L Watson, Valerie Brown, Jenny Hendriks, Maria Grazia Pau, Isabella Versteege, Edison Wiesken, Jerald Sadoff, Issa Nebie, Sodiomon B Sirima

    Published 2013-01-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Ad35.CS.01-RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve Adults.

    Ad35.CS.01-RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve Adults. by Christian F Ockenhouse, Jason Regules, Donna Tosh, Jessica Cowden, April Kathcart, James Cummings, Kristopher Paolino, James Moon, Jack Komisar, Edwin Kamau, Thomas Oliver, Austin Chhoeu, Jitta Murphy, Kirsten Lyke, Matthew Laurens, Ashley Birkett, Cynthia Lee, Rich Weltzin, Ulrike Wille-Reece, Martha Sedegah, Jenny Hendriks, Isabella Versteege, Maria Grazia Pau, Jerold Sadoff, Yannick Vanloubbeeck, Marc Lievens, Dirk Heerwegh, Philippe Moris, Yolanda Guerra Mendoza, Erik Jongert, Joe Cohen, Gerald Voss, W Ripley Ballou, Johan Vekemans

    Published 2015-01-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: